Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib
Journal article published in 2015 by
C. F. Spraggs,
L. R. Parham,
K. Song,
L. P. Briley,
T. Johnson 
,
M. Russo,
H. Tada,
A. du Bois,
C.-F. Xu
,
M. Russo,
H. Tada,
A. du Bois,
C.-F. Xu
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 